Health Policy Watch - Global health news reportingApr 17
💉 A major #HIV prevention scale-up: the US and The GlobalFund are expanding #lenacapavir access to reach 3 million people. The twice-yearly injectable could reshape prevention, but delivery, equity, and speed will determine impact. ✍️ @[email protected] @[email protected] @[email protected] 📰⬇️ and 🔁🙏

One Million More People To Get...
One Million More People To Get HIV ‘Miracle’ Drug Lenacapavir As US, Global Fund Expand Access - Health Policy Watch

The United States and the Global Fund will support three million people to get lenacapavir, the twice-a-year HIV injection that is almost 100% successful in

Health Policy Watch
drjudystoneApr 16

Why is #Gilead refusing to sell Lenacapavir to #MSF? Breakthrough HIV Drug Is Out Of Reach For Many Who Need It Most via @forbes https://www.forbes.com/sites/judystone/2026/04/16/breakthrough-hiv-drug-is-out-of-reach-for-many-who-need-it-most/

#Lenacapavir #ResearchEthics #bioethics

Breakthrough HIV Drug Is Out Of Reach For Many Who Need It Most

Len is a gamechanging drug to prevent HIV infections, priced by Gilead at $28,200. Limited drug is available at cost to low-income countries. Research ethics are discussed.

Forbes
Outras PalavrasApr 13

Obras da BR-319 ameaçam a biossegurança global, alerta Science

• BR-319 levará a novas pandemias? • Rede de proteção a mulheres • Avança a Síndrome Respiratória Aguda Grave • E MAIS: emendas parlamentares; Lenacapavir; rotulagem de alimentos •

https://outraspalavras.net/outrasaude/obras-da-br-319-ameacam-a-biosseguranca-global-alerta-science/

Show thread🌈 breaking ranks.Apr 8

2/2

"We call on #Gilead to respond by April 13, 2026 clarifying:

1. Whether you will sell #lenacapavir directly to #MSF?
2. If not, why, given your stated production capacity?
3. If yes, at what price and how soon can delivery begin?

The #health of many people depends on your answers to these questions."

Via @sham |s faboulous newsletter what happened last week in Asia, Africa and the Americas.

🌈 breaking ranks.Apr 8

1/2
"#Lenacapavir, a twice-yearly, long-acting #HIV prevention tool, represents one of the most promising advances towards ending #AIDS [.]. #Gilead has an obligation to ensure that access is not restricted by where people live, who they are, or what their country can pay. [.] this drug’s development was supported by public funding and through the trust of communities who participated in clinical trials, many of them in countries now excluded from affordable access [.]."

https://www.doctorswithoutborders.org/latest/prevention-should-not-be-privilege-msf-calls-gilead-direct-access-lenacapavir

Headlines AfricaApr 2
Africa: Gilead Under Fire for Not Selling HIV Drug Lenacapavir to MSF: [allAfrica] Pharmaceutical company Gilead Sciences has come under mounting pressure after refusing to sell its breakthrough HIV prevention drug, lenacapavir, directly to Médecins Sans Frontières (MSF), despite repeated requests. http://newsfeed.facilit8.network/TRqtQB #HIV #Lenacapavir #GileadSciences #MSF #Pharmaceuticals
Whoa 🤯 in Slow-MoMar 27
Kenya and Zimbabwe are among the first African countries to offer #lenacapavir, a game-changing #HIV prevention injection that's shown 100% efficacy 💉. You only need it twice a year. Kenya is already giving it out free at public clinics 🇰🇪, while Zimbabwe is rolling it out across 24 sites 🇿🇼.

Kenya to offer patients free s...
Kenya to offer patients free six-month HIV 'breakthrough' prevention jab

Kenya's health authorities have begun administering lenacapavir, a long-acting HIV prevention drug delivered by injection that offers protection for six months. The treatment will be available free of charge to eligible patients, making Kenya one of the first countries to introduce this new prevention therapy.

RFI
Headlines AfricaMar 5
South Africa pushes for local production of HIV prevention drug lenacapavir http://newsfeed.facilit8.network/TRJfVw #HIVPrevention #Lenacapavir #SouthAfrica #Pharmaceuticals #LocalProduction
Outras PalavrasFeb 27

Patentes: o perigo de transferir decisão ao Congresso

Uma análise sobre os projetos de lei relacionados à propriedade intelectual de medicamentos, nos últimos anos, mostra como os parlamentares são avessos a mudanças na legislação atual. Hoje, decisão cabe ao Executivo – e deve continuar assim

https://outraspalavras.net/outrasaude/patentes-o-perigo-de-transferir-a-decisao-ao-congresso/

Outras PalavrasFeb 27

Mounjaro e lenacapavir: o que os aproxima?

Projetos de lei abrem caminho para quebrar patentes de caneta emagrecedora e medicamento para HIV. E levantam debate: leis de propriedade intelectual servem ao interesse público ou à privatização de saberes que deveriam ser Comuns?

https://outraspalavras.net/outrasaude/mounjaro-e-lenacapavir-o-que-os-aproxima/